CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)*
Konrad Reinhart(Humboldt-Universität zu Berlin), John P. Pribble(Apple (Israel)), Steven M. Opal(Brown University), Sonia Souza(Stellenbosch University), Terence Turner(Aetna (United States)), Tim Axtelle(Aetna (United States)), Albert Bruining(Aetna (United States)), Jack J. M. Ligtenberg, Lyle L. Moldawer(University of Florida), Jan Bakker(Intensive Care Society), Thomas Glück(Twitter (United States)), Klaus Tschaikowsky
Cited by 80
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Critical Care Medicine|2003|6k
Genomic responses in mouse models poorly mimic human inflammatory diseases
|Proceedings of the National Academy of Sciences|2013|3k